Submission of Unaudited Financial Results for the quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories reported Q3 FY26 revenue from operations of Rs 5,223.53 lakhs, surging about 261% year-on-year from Rs 1,445.88 lakhs, driven by its new focus on pharmaceutical active ingredients (bulk drugs). Nine-month revenue nearly tripled to Rs 11,507.83 lakhs (vs Rs 4,076.43 lakhs a year ago). However, net profit for Q3 came in at Rs 235.73 lakhs, marginally lower YoY (Rs 244.46 lakhs), while 9M FY26 PAT grew modestly to Rs 702.96 lakhs from Rs 618.05 lakhs. Profit Before Tax margin compressed sharply to about 6% in Q3 FY26 from nearly 21% in Q3 FY25, as the cost base scaled up faster than expected. The auditor (Sathuluri & Co) issued a clean limited review report with no qualifications or emphasis of matter.
The strong revenue jump reflects successful ramp-up of the newly pivoted pharma ingredients business, but significant margin compression and tepid profit growth may cap near-term upside; shareholders should track margin recovery and the sustainability of the topline momentum.